Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib for steroid-refractory graft-versus-host disease
ChiCTR2300069437Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Mar 2023
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of baricitinib in graft-versus-host disease (GVHD) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Objective remission rate at Day 56 and Treatment-related mortality at Day 56. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
baricitinib
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on ChiCTR2300069437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069437.